SYK is a critical regulator of FLT3 in acute myeloid leukemia.

[1]  M. Crackower,et al.  Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. , 2013, American journal of respiratory cell and molecular biology.

[2]  Fatima Al-Shahrour,et al.  In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. , 2013, Cancer cell.

[3]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[4]  H. Urlaub,et al.  β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. , 2013, Blood.

[5]  B. Druker,et al.  The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[6]  G. Nybakken,et al.  Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. , 2012, Blood.

[7]  S. Armstrong,et al.  Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. , 2012, Trends in immunology.

[8]  F. Giles,et al.  Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia , 2012, Leukemia.

[9]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[10]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[11]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[12]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[13]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[14]  T. Naoe,et al.  FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling , 2011, European journal of haematology.

[15]  E. Estey,et al.  Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Sattler,et al.  Drug resistance in mutant FLT3-positive AML , 2010, Oncogene.

[17]  Victor L. J. Tybulewicz,et al.  The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.

[18]  J. Holch,et al.  The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma , 2010, The Journal of experimental medicine.

[19]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[20]  Tina N. Davis,et al.  Proteomic and genetic approaches identify Syk as an AML target. , 2009, Cancer cell.

[21]  S. Akinaga,et al.  A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. , 2009, Blood.

[22]  N. Donato,et al.  Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. , 2008, Blood.

[23]  Nick Holford,et al.  Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. , 2006, Blood.

[24]  D. Payan,et al.  R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[25]  M. Roussel,et al.  Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Tomasson,et al.  c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. , 2005, Blood.

[27]  P. De,et al.  Molecular Basis for a Direct Interaction between the Syk Protein-tyrosine Kinase and Phosphoinositide 3-Kinase* , 2005, Journal of Biological Chemistry.

[28]  R. Clark,et al.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. , 2004 .

[29]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[30]  M. Tanimoto,et al.  Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). , 2001, Blood.

[31]  H. Umehara,et al.  Co-stimulation of T cells with CD2 augments TCR-CD3-mediated activation of protein tyrosine kinase p72syk, resulting in increased tyrosine phosphorylation of adapter proteins, Shc and Cbl. , 1998, International immunology.

[32]  R. Geahlen,et al.  Syk Activation and Dissociation from the B-cell Antigen Receptor Is Mediated by Phosphorylation of Tyrosine 130* , 1997, The Journal of Biological Chemistry.